Herantis Pharma expands on timeline for Lymfactin studies
Herantis Pharma expands on timeline for Lymfactin® studies Herantis Pharma PlcCompany release 27 December 2017 at 9:00 am Herantis Pharma Plc's ("Herantis") announces a slight delay in completing patient recruitment in its clinical Phase 1 study with the company's investigational gene therapy product Lymfactin®. Patient recruitment is expected to be completed in the first quarter of 2018 instead of by the end of 2017 as previously estimated and announced. Thanks to the data cumulated so far meeting expectations in the Phase 1 study, Herantis is preparing the submission of a